Vir Biotechnology (VIR) News Today

Vir Biotechnology (NASDAQ:VIR) will be releasing earnings after the market closes on Thursday, August 1, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=610504)

Mirae Asset Global Investments Co. Ltd. trimmed its holdings in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 76.7% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 49,525 shares of the company's stock after sell

Shares of Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the seven brokerages that are covering the firm, Marketbeat Ratings reports. Three analysts have rated the stock with a hold recommendation and four have issued a buy re

Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) was the recipient of a large decline in short interest in the month of June. As of June 30th, there was short interest totalling 4,760,000 shares, a decline of 30.3% from the June 15th total of 6,830,000 shares. Currently, 5.3% of the company's shares are short sold. Based on an average daily volume of 1,130,000 shares, the short-interest ratio is presently 4.2 days.

Vir Biotechnology (NASDAQ:VIR) Shares Up 11.2%

Vanguard Group Inc. grew its holdings in shares of Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 9.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 12,297,139 shares of the company's stock after p

Shares of Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the seven ratings firms that are currently covering the company, Marketbeat.com reports. Three research analysts have rated the stock with a hold recommendation and four ha

Vir Biotechnology (NASDAQ:VIR) Sees Strong Trading Volume

Vir Biotechnology (NASDAQ:VIR) Shares Down 5.5%

Vir Biotechnology (NASDAQ:VIR) Shares Gap Down to $11.23

Rafferty Asset Management LLC cut its stake in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 24.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 398,970 shares of the company's stock after selling

Vir Biotechnology (NASDAQ:VIR) Trading Down 8%

Morgan Stanley boosted their target price on shares of Vir Biotechnology from $12.00 to $15.00 and gave the stock an "equal weight" rating in a research report on Thursday.

Needham & Company LLC boosted their price objective on Vir Biotechnology from $15.00 to $19.00 and gave the stock a "buy" rating in a research note on Wednesday.

HC Wainwright restated a "buy" rating and issued a $110.00 target price on shares of Vir Biotechnology in a research report on Wednesday.

Vir Biotechnology (NASDAQ:VIR) Shares Gap Up to $10.58

Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) has been given a consensus rating of "Moderate Buy" by the seven analysts that are currently covering the company, MarketBeat reports. Three research analysts have rated the stock with a hold recommendation and four have assigned a buy recomme

Panagora Asset Management Inc. purchased a new position in shares of Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) in the fourth quarter, according to its most recent filing with the SEC. The firm purchased 94,516 shares of the company's stock, valued at approximately $951,000. Panagora Asset

Vir Biotechnology (NASDAQ:VIR) Stock Price Up 3.4%

Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) - Research analysts at HC Wainwright increased their FY2024 earnings per share estimates for shares of Vir Biotechnology in a research report issued on Tuesday, May 7th. HC Wainwright analyst P. Trucchio now anticipates that the company will post

HC Wainwright reaffirmed a "buy" rating and set a $110.00 price objective on shares of Vir Biotechnology in a research report on Tuesday.

Vir Biotechnology (NASDAQ:VIR - Get Free Report) posted its earnings results on Thursday. The company reported ($0.48) EPS for the quarter, topping the consensus estimate of ($0.99) by $0.51. The company had revenue of $56.38 million during the quarter, compared to the consensus estimate of $11.71 million. Vir Biotechnology had a negative net margin of 713.69% and a negative return on equity of 34.92%. The firm's revenue for the quarter was down 10.5% on a year-over-year basis. During the same period in the previous year, the firm posted ($1.06) earnings per share.

Needham & Company LLC reissued a "buy" rating and set a $15.00 price objective on shares of Vir Biotechnology in a report on Friday.